Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W D Ludwig

Showing results (31-40 of 267) with videos related to

Pageof 27
Sort By:
Der Internist|June 1, 1987
[Thrombotic thrombocytopenic purpura within the scope of disseminated tumor disease]J Teichmann, G Sieber, W D Ludwig, et al.
Journal of Computer Assisted Tomography|November 1, 1987
MR imaging of post-traumatic pseudoaneurysm of the deep femoral arteryW D Ludwig, W T Yuh, W J Montgomery
Haematology and Blood Transfusion|January 1, 1987
Alteration of blast phenotype after low-dose cytarabine in children with acute myeloid leukemiaF Berthold, J Harbott, W D Ludwig, et al.
Blut|September 1, 1985
B-cell function in AIDSG Sieber, H Teichmann, W D Ludwig, et al.
Der Internist|June 15, 2010
[Hematopoietic growth factors. Possibilities and limitations]T K Held, M O Hildebrandt, W-D Ludwig
Cancer|May 15, 1989
Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patientsJ V Teichmann, G Sieber, W D Ludwig, et al.
Journal of Interferon Research|February 1, 1988
Modulation of immune functions by long-term treatment with recombinant interferon-alpha 2 in a patient with hairy-cell leukemiaJ V Teichmann, G Sieber, W D Ludwig, et al.
Haematology and Blood Transfusion|January 1, 1990
Lymphokine-activated killer (LAK) cells against human leukemia: augmentation of LAK-cell cytotoxicity by combinations of lymphokines or cytokinesJ V Teichmann, W D Ludwig, H Seibt-Jung, et al.
Leukemia|March 17, 2000
Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cellsU Kordes, D Krappmann, V Heissmeyer, et al.
Leukemia|August 1, 1993
SIL-TAL1 deletion in T-cell acute lymphoblastic leukemiaJ W Janssen, W D Ludwig, W Sterry, et al.
Pageof 27

Showing results (31-40 of 267) with videos related to

Sort By:
Pageof 27
Der Internist|June 1, 1987
[Thrombotic thrombocytopenic purpura within the scope of disseminated tumor disease]J Teichmann, G Sieber, W D Ludwig, et al.
Journal of Computer Assisted Tomography|November 1, 1987
MR imaging of post-traumatic pseudoaneurysm of the deep femoral arteryW D Ludwig, W T Yuh, W J Montgomery
Haematology and Blood Transfusion|January 1, 1987
Alteration of blast phenotype after low-dose cytarabine in children with acute myeloid leukemiaF Berthold, J Harbott, W D Ludwig, et al.
Blut|September 1, 1985
B-cell function in AIDSG Sieber, H Teichmann, W D Ludwig, et al.
Der Internist|June 15, 2010
[Hematopoietic growth factors. Possibilities and limitations]T K Held, M O Hildebrandt, W-D Ludwig
Cancer|May 15, 1989
Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patientsJ V Teichmann, G Sieber, W D Ludwig, et al.
Journal of Interferon Research|February 1, 1988
Modulation of immune functions by long-term treatment with recombinant interferon-alpha 2 in a patient with hairy-cell leukemiaJ V Teichmann, G Sieber, W D Ludwig, et al.
Haematology and Blood Transfusion|January 1, 1990
Lymphokine-activated killer (LAK) cells against human leukemia: augmentation of LAK-cell cytotoxicity by combinations of lymphokines or cytokinesJ V Teichmann, W D Ludwig, H Seibt-Jung, et al.
Leukemia|March 17, 2000
Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cellsU Kordes, D Krappmann, V Heissmeyer, et al.
Leukemia|August 1, 1993
SIL-TAL1 deletion in T-cell acute lymphoblastic leukemiaJ W Janssen, W D Ludwig, W Sterry, et al.
Pageof 27